Myeloma EHA 2025 preview
The European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, will take place from 12 – 15 June in Milan, Italy. The meeting will bring together experts from across the globe…
The European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, will take place from 12 – 15 June in Milan, Italy. The meeting will bring together experts from across the globe…
On the 23 May 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of two belantamab mafodotin combinations for the treatment of patients with relapsed and/or refractory myeloma. The first combination is…
On 23th April 2025, the European Commission has granted conditional marketing approval of linvoseltamab to treat adults with relapsed and refractory myeloma. Conditional approval means that linvoseltamab will be reassessed for safety and efficacy when…
On 27th February 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma. The CHMP is the European Medicines Agency’s committee…
My name is Maureen , and I was diagnosed with Myeloma in 2017 at the age of 55 and was fortunate to have been invited to join a clinical trial. This was successful and my myeloma…
My name is Ritva, and I live in Finland. I got my myeloma diagnosis four and a half years ago, when I was 63 years old. The first days after the diagnosis, I thought this…
My name is Ariunsanaa and last year my mother was diagnosed with myeloma. At that time, both my sibling and I were living abroad. We soon realised there was no available treatment in our hometown,…
My name is Wouter, I am living in The Netherlands, and I am 55 years old. In March 2024, I was diagnosed with myeloma, which turned my world upside down. One of the biggest challenges…